Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31308Editorial articleПередовая статьяReview ArticleStrategy for the use of chondroprotectors in osteoarthrosisСтратегия применения хондропротекторов при остеоартрозеNoskovS MНосковС МLavrukhinaA AЛаврухинаА АShirokovaK IuШироковаК ЮPrianichnikovaA AПряничниковаА АЯрославская государственная медицинская академия Минздрава России15052013855VOL 85, NO5 ()ТОМ 85, №5 (2013)929410042020Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31308

Symptomatic slow-acting drugs (chondroprotectors) as different dosage forms have widespread application in the treatment of osteoarthrosis (OA) at different locations. The literature review considers their possible effect on carbohydrate metabolism, which is particularly important due to the high prevalence of diabetes mellitus in patients with OA. Current clinical recommendations for the use of chondroprotectors in the therapy of OA are given.

Аннотация. Симптоматические препараты медленного действия (хондропротекторы) в виде разных лекарственных форм находят широкое применение при лечении остеоартроза (ОА) различных локализаций. В обзоре литературы рассматривается их возможное влияние на углеводный обмен, что особенно важно ввиду высокой распространенности сахарного диабета у больных ОА. Представлены современные клинические рекомендации по применению хондропротекторов в терапии ОА.

osteoarthrosisdiabetes mellitussymptomatic slow-acting drugschondroprotectorsостеоартрозсахарный диабетсимптоматические препараты медленного действияхондропротекторыRadimer K., Bindewald B., Hughes J. et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 2004; 160 (4): 339-349.Jerosch J. Effects of glucosamine and chondroitin sulfate on cartilage metabolism in OA: outlook on other nutrient partners especially omega-3 fatty acids. Int J Rheumatol 2011 doi:10.1155/2011/969012.Pecchi E., Priam S., Mladenovic Z. et al. A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E2 and matrix metalloproteinases synthesis in interleukin-1Β-stimulated osteoblasts. Osteoarthritis Cartilage 2012; 20 (2): 127-135.Bauerova K., Ponist S., Kuncirova V. et al. Chondroitin sulfate effect on induced arthritis in rats. Osteoarthritis Cartilage 2011; 19 (11): 1373-1379.Volpi N. Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule. Inflammopharmacology 2011; 19 (6): 299-306.Anderson J.W., Nicolosi R.J., Borzelleca J.F. Glucosamine effects in humans: A review of effects on glucose metabolism, side effects, safety considerations, and efficacy. Food Chem Toxicol 2005; 43 (2): 187-201.Silbert J.E. Dietary glucosamine under question. Glycobiology 2009; 19 (6): 564-567.Wandel S., Juni P., Tendal B. et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341: 4675.Vista E.S., Lau C.S. What about supplements for osteoarthritis? A critical and evidenced-based review. Intern J Rheum Dis 2011; 14: 152-158.Towheed T.E., Maxwell L., Anastassiades T.P. et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005. 2; CD002946.Reichenbach S., Sterchi R., Scherer M. et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007; 146 (8): 580-590.Hochberg M.C. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 2010; 18 (Suppl 1): 28-31.Kahan A., Uebelhart D., De Vathaire F. et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009; 60: 524-533.Lee Y.H., Woo J.H., Choi S.J. et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int 2010; 30 (3): 357-363.Wildi L.M., Raynauld J.P., Martel-Pelletier J. et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011; 70 (6): 982-989.Vlad S.C., LaValley M.P., McAlindon T.E., Felson D.T. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 2007; 56: 2267-2277.Hochberg M.C., Altman R.D., April K.T. et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64 (4): 455-474.Sawitzke A.D., Shi H., Finco M.F. et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010; 69 (8): 1459-1464.Dostrovsky N.R., Towheed T.E., Hudson R.W., Anastassiades T.P. The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature. Osteoarthritis Cartilage 2011; 19 (4): 375-380.Simon R.R., Marks V., Leeds A.R., Anderson J.W. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev 2011; 27 (1): 14-27.Daren A.S., Allison A., Mark D.H. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus. Arch Intern Med 2003; 163: 1587-1590.Pham T., Cornea A., Blick K.E. et al. Oral glucosamine in doses used to treat osteoarthritis worsens insulinresistance. Am J Med Sci 2007; 333 (6): 333-339.Muniyappa R., Karne R.J., Hall G. et al. Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes 2006; 55 (11): 3142-3150.Biggee B.A., Blinn C.M., Nuite M. et al. Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. Ann Rheum Dis 2007; 66 (2): 260-262.Albert S.G., Oiknine R.F., Parseghian S. et al. The effect of glucosamine on Serum HDL cholesterol and apolipoprotein A I levels in people with diabetes. Diabetes Care 2007; 30 (11): 2800-2803.Palma Dos Reis R., Giacovelli G., Girolami F. et al. Crystalline glucosamine sulfate in the treatment of osteoarthritis: evidence of long-term cardiovascular safety from clinical trials. Open Rheumatol J 2011; 5: 69-77.